Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Gandhi MJ, Pierce RA, Zhang L, Moon MR, Despotis GJ, Moazami N.

J Cardiothorac Surg. 2007 Jul 6;2:32.

2.

Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Transfusion. 2013 Apr;53(4):798-804. doi: 10.1111/j.1537-2995.2012.03801.x. Epub 2012 Jul 31.

PMID:
22845023
3.

High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII.

Bruckner BA, DiBardino DJ, Ning Q, Adeboygeun A, Mahmoud K, Valdes J, Eze J, Allison PM, Cooley DA, Gregoric ID, Frazier OH.

J Heart Lung Transplant. 2009 Aug;28(8):785-90. doi: 10.1016/j.healun.2009.04.028.

PMID:
19632574
4.

Efficacy and Safety of Recombinant Factor VII as Rescue for Severe Perioperative Bleeding in HeartMate II Recipients.

Karimi A, Daigle SS, Smith WB, Janelle GM, Klodell CT.

J Card Surg. 2015 Jun;30(6):500-5. doi: 10.1111/jocs.12555. Epub 2015 May 4.

PMID:
25939953
5.

Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients.

AlGahtani FH, Alshaikh M, AlDiab A.

Ann Saudi Med. 2010 May-Jun;30(3):198-202. doi: 10.4103/0256-4947.62830.

6.

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Pediatr Hematol Oncol. 2008 Jun;25(4):301-11. doi: 10.1080/08880010802016904.

PMID:
18484474
7.

Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.

Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J.

Ann Thorac Surg. 2006 Mar;81(3):875-9.

PMID:
16488687
8.

Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.

Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA; Australian and New Zealand Haemostasis Registry.

Anesth Analg. 2009 Dec;109(6):1908-15. doi: 10.1213/ANE.0b013e3181c039e6.

PMID:
19923520
9.

Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.

Hollis AL, Lowery AV, Pajoumand M, Pham SM, Slejko JF, Tanaka KA, Mazzeffi M.

Ann Card Anaesth. 2016 Jul-Sep;19(3):418-24. doi: 10.4103/0971-9784.185523.

10.

Recombinant activated factor VII use in critically ill infants with active hemorrhage.

Jen H, Shew S.

J Pediatr Surg. 2008 Dec;43(12):2235-8. doi: 10.1016/j.jpedsurg.2008.08.053.

PMID:
19040942
11.

Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.

Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J.

Vox Sang. 2014 Jan;106(1):75-82. doi: 10.1111/vox.12067. Epub 2013 Jul 1.

PMID:
23815226
12.

Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.

Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS.

Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7. doi: 10.1016/j.athoracsur.2008.01.089.

PMID:
18442563
13.

Recombinant factor VIIa for refractory bleeding following orthotopic heart transplantation.

Flynn JD, Pajoumand M, Camp PC Jr, Jahania MS, Ramaiah C, Akers WS.

Ann Pharmacother. 2004 Oct;38(10):1639-42. Epub 2004 Aug 31.

PMID:
15340124
14.

Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.

Mitsiakos G, Papaioannou G, Giougi E, Karagianni P, Garipidou V, Nikolaidis N.

J Pediatr Hematol Oncol. 2007 Mar;29(3):145-50.

PMID:
17356391
15.

Predicting response to rFVIIa in neonates with intractable bleeding or severe coagulation disturbances.

Gkiougki E, Mitsiakos G, Chatziioannidis E, Papadakis E, Nikolaidis N.

J Pediatr Hematol Oncol. 2013 Apr;35(3):221-6. doi: 10.1097/MPH.0b013e318286d27e.

PMID:
23511491
16.

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Ann Thorac Surg. 2008 Mar;85(3):836-44. doi: 10.1016/j.athoracsur.2007.06.076.

PMID:
18291152
17.

Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.

Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.

Ann Thorac Surg. 2006 Nov;82(5):1779-83.

PMID:
17062247
18.

Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.

Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM.

Drugs R D. 2015 Jun;15(2):187-94. doi: 10.1007/s40268-015-0093-9.

19.

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.

Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.

Vox Sang. 2004 Jul;87(1):34-40. Review.

PMID:
15260820
20.

Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.

Rao VK, Lobato RL, Bartlett B, Klanjac M, Mora-Mangano CT, Soran PD, Oakes DA, Hill CC, van der Starre PJ.

J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1221-6. doi: 10.1053/j.jvca.2014.04.015.

PMID:
25281040

Supplemental Content

Support Center